185 related articles for article (PubMed ID: 19247981)
1. Spending on new drug development1.
Adams CP; Brantner VV
Health Econ; 2010 Feb; 19(2):130-41. PubMed ID: 19247981
[TBL] [Abstract][Full Text] [Related]
2. Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA; Feldman L; Seckler A; Wilson A
Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
[TBL] [Abstract][Full Text] [Related]
3. Estimating the cost of new drug development: is it really 802 million dollars?
Adams CP; Brantner VV
Health Aff (Millwood); 2006; 25(2):420-8. PubMed ID: 16522582
[TBL] [Abstract][Full Text] [Related]
4. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
5. Drug costs: research and development costs: the great illusion.
Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
[TBL] [Abstract][Full Text] [Related]
6. Managing clinical grant costs.
Glass HE; Hollander K
Contemp Clin Trials; 2009 May; 30(3):221-6. PubMed ID: 19470309
[TBL] [Abstract][Full Text] [Related]
7. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
8. [Does the public sector have an independent research role in the development of drugs?].
Poulsen HE; Grønlykke TB
Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
[TBL] [Abstract][Full Text] [Related]
9. How some patients in new-drug trials can get cut off.
Anand G
Wall St J (East Ed); 2003 Dec; ():A1, A11. PubMed ID: 14971381
[No Abstract] [Full Text] [Related]
10. Economic advantage of pharmacogenomics - clinical trials with genetic information.
Ohashi W; Mizushima H; Tanaka H
Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
[TBL] [Abstract][Full Text] [Related]
11. [Clinical drug trials in Germany--an assessment of current status from the viewpoint of industry].
Baumbauer E
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():646-50. PubMed ID: 9101960
[TBL] [Abstract][Full Text] [Related]
12. Prescription drugs and health care reform.
Gibaldi M
Pharmacotherapy; 1993; 13(6):583-9. PubMed ID: 8302681
[No Abstract] [Full Text] [Related]
13. New estimates of drug development costs.
Frank RG
J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
[No Abstract] [Full Text] [Related]
14. Wall Street and clinical trials.
Steinbrook R
N Engl J Med; 2005 Sep; 353(11):1091-3. PubMed ID: 16162879
[No Abstract] [Full Text] [Related]
15. More Chinese get free drugs in clinical trials.
Berton E
Wall St J (East Ed); 2006 Feb; ():B1, B8. PubMed ID: 16528877
[No Abstract] [Full Text] [Related]
16. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
17. Managing physician financial conflicts of interest in clinical trials conducted in the private practice setting.
Williams KM
Food Drug Law J; 2004; 59(1):45-77. PubMed ID: 15190925
[No Abstract] [Full Text] [Related]
18. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
19. A decision analytic approach to a futility analysis of a phase II pharmaceutical study.
Pallay A
J Biopharm Stat; 2001 Nov; 11(4):209-25. PubMed ID: 12018776
[TBL] [Abstract][Full Text] [Related]
20. Spending on medicines in Israel in an international context.
Sax P
Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
